CHF Care Plan Diagnosis: A Comprehensive Guide for Healthcare Professionals

Introduction

Heart failure (HF), often referred to as Congestive Heart Failure (CHF), is a prevalent and intricate clinical syndrome arising from diverse functional or structural cardiac disorders. This condition impairs the heart’s ability to effectively fill with blood or eject it into systemic circulation, thereby failing to meet the body’s metabolic demands. CHF is not a disease in itself but rather a consequence of various underlying cardiac pathologies. The majority of individuals diagnosed with CHF exhibit symptoms stemming from compromised left ventricular myocardial function. Common clinical manifestations include dyspnea, fatigue, reduced exercise capacity, and fluid retention, clinically evident as pulmonary and peripheral edema.[1]

Classifying heart failure based on left ventricular ejection fraction (LVEF) is crucial for diagnosis and management. Heart failure with reduced ejection fraction (HFrEF) is defined by an LVEF of 40% or less, while heart failure with preserved ejection fraction (HFpEF) is characterized by an LVEF greater than 40%.[2] Accurate Chf Care Plan Diagnosis is essential to guide effective treatment strategies and improve patient outcomes. This article provides a comprehensive overview of CHF care plan diagnosis, management, and nursing considerations, emphasizing a holistic approach to patient care.

Nursing Diagnoses in CHF Care Plan

Developing an effective CHF care plan diagnosis involves identifying key nursing diagnoses that address the multifaceted needs of patients. These diagnoses guide nursing interventions and contribute to a comprehensive care strategy. Common nursing diagnoses associated with CHF include:

• Decreased Cardiac Output: Related to structural or functional impairment of the heart.
• Activity Intolerance: Resulting from decreased cardiac output and impaired oxygen delivery.
• Excess Fluid Volume: Due to the body’s compensatory mechanisms and impaired renal function.
• Risk for Impaired Skin Integrity: Secondary to edema, poor tissue perfusion, and immobility.
• Ineffective Tissue Perfusion: Associated with reduced cardiac output and circulatory compromise.
• Ineffective Breathing Pattern: Linked to pulmonary congestion and fluid overload.
• Impaired Gas Exchange: Resulting from pulmonary edema and ventilation-perfusion mismatch.
• Fatigue: A common symptom due to reduced cardiac output and metabolic changes.
• Anxiety: Related to the chronic nature of the illness, symptoms, and lifestyle changes.

Etiology of Congestive Heart Failure

CHF is a syndrome with diverse etiologies, encompassing disorders affecting various cardiac structures and functions. These include diseases of the pericardium, myocardium, endocardium, cardiac valves, vasculature, and metabolic abnormalities. Understanding the underlying cause is crucial for effective CHF care plan diagnosis and targeted treatment.

The most frequent causes of systolic dysfunction (HFrEF) are:

• Idiopathic Dilated Cardiomyopathy (DCM)
• Coronary Heart Disease (Ischemic Heart Disease)
• Hypertension (Uncontrolled)
• Valvular Heart Disease

For diastolic dysfunction (HFpEF), common causes are similar, with the addition of:

• Hypertrophic Obstructive Cardiomyopathy
• Restrictive Cardiomyopathy[1]

Other less common but important causes include myocarditis (often viral), peripartum cardiomyopathy, and infiltrative cardiomyopathies like amyloidosis and sarcoidosis. Tachycardia-induced cardiomyopathy and high-output heart failure (due to conditions like severe anemia or hyperthyroidism) can also lead to CHF.[18, 22]

Risk Factors for CHF Development

Identifying risk factors is a crucial aspect of CHF care plan diagnosis and preventative strategies. Several factors significantly increase the likelihood of developing heart failure:

• Coronary Artery Disease (CAD)
• Myocardial Infarction (MI)
• Hypertension
• Diabetes Mellitus
• Obesity
• Smoking
• Alcohol Use Disorder
• Atrial Fibrillation (AFib)
• Thyroid Diseases (Hyperthyroidism and Hypothyroidism)
• Congenital Heart Disease
• Aortic Stenosis

Modifiable risk factors such as hypertension, diabetes, obesity, smoking, and alcohol use are critical targets for lifestyle interventions and preventive measures in a CHF care plan diagnosis and management strategy. Addressing these risk factors can significantly reduce the incidence and progression of heart failure. [27]

Clinical Assessment and Symptomatology of CHF

A thorough assessment is paramount in CHF care plan diagnosis. Symptoms of heart failure arise from two primary mechanisms: fluid overload and reduced cardiac output.

Symptoms due to Fluid Overload:

• Dyspnea (Shortness of breath), especially on exertion or lying flat (orthopnea)
• Orthopnea (Difficulty breathing when lying flat)
• Paroxysmal Nocturnal Dyspnea (PND) (Sudden breathlessness at night)
• Edema (Peripheral swelling in ankles, legs, sacrum)
• Pain from Hepatic Congestion (Right upper quadrant discomfort)
• Abdominal Distention (Ascites)

Symptoms due to Reduced Cardiac Output:

• Fatigue and Weakness, particularly with physical activity
• Dizziness or Lightheadedness
• Exercise Intolerance
• Cognitive Impairment in severe cases

Presentation based on Acuity:

• Acute and Subacute Presentations (Days to Weeks): Characterized by prominent shortness of breath at rest and/or exertion, orthopnea, PND, and right upper quadrant pain due to acute liver congestion. Palpitations may occur if arrhythmias develop.
• Chronic Presentations (Months): Fatigue, anorexia, abdominal distension, and peripheral edema may be more noticeable than dyspnea. Anorexia can be secondary to poor splanchnic perfusion, bowel edema, and nausea from liver congestion.[1]

Characteristic Physical Examination Findings:

• Pulsus Alternans: Alternating strong and weak peripheral pulses, indicating severe left ventricular dysfunction.
• Displaced Apical Impulse: Laterally displaced point of maximal impulse (PMI) suggesting left ventricular enlargement.
• S3 Gallop: A low-frequency heart sound in early diastole, a sensitive indicator of ventricular dysfunction.
• Peripheral Edema: Pitting edema in dependent areas.
• Pulmonary Rales (Crackles): Indicating pulmonary congestion.
• Jugular Venous Distension (JVD): Elevated jugular venous pressure, reflecting increased right atrial pressure.

New York Heart Association (NYHA) Functional Classification

The NYHA classification is a widely used system to categorize the severity of heart failure based on symptoms and functional limitations, which is important for CHF care plan diagnosis and staging: [3]

• Class I: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, dyspnea, or palpitations.
• Class II: Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in fatigue, palpitations, or dyspnea.
• Class III: Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes fatigue, palpitations, or dyspnea.
• Class IV: Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest.

Understanding the NYHA class helps tailor the CHF care plan diagnosis and treatment intensity to the patient’s functional capacity.

Diagnostic Evaluation in CHF Care Plan Diagnosis

Definitive CHF care plan diagnosis requires a combination of clinical assessment and diagnostic testing to confirm the presence of heart failure, identify the underlying cause, and assess disease severity.

Essential Diagnostic Tests:

• Electrocardiogram (ECG): Detects evidence of prior myocardial infarction, acute ischemia, arrhythmias (like atrial fibrillation), and left ventricular hypertrophy. While not diagnostic for CHF itself, it can point to underlying cardiac issues.
• Chest X-ray: Reveals cardiomegaly (increased cardiac-to-thoracic ratio >50%), pulmonary vascular congestion (cephalization of pulmonary vessels, Kerley B-lines), and pleural effusions.
• Blood Tests:
  • Cardiac Troponin (T or I): To rule out acute myocardial infarction.
  • Complete Blood Count (CBC): To assess for anemia, which can exacerbate HF.
  • Serum Electrolytes: Including sodium, potassium, and magnesium, as imbalances are common in CHF and can affect management.
  • Blood Urea Nitrogen (BUN) and Creatinine: To evaluate renal function, which is often impaired in CHF and affected by diuretic therapy.
  • Liver Function Tests (LFTs): To assess for hepatic congestion.
  • Brain Natriuretic Peptide (BNP) or N-terminal pro-BNP (NT-proBNP): Elevated levels strongly support the diagnosis of heart failure, particularly in dyspneic patients. BNP is a crucial biomarker in CHF care plan diagnosis, adding significant diagnostic value over history and physical exam alone.[37, 41]
• Transthoracic Echocardiogram (TTE): The cornerstone of CHF care plan diagnosis. TTE assesses:
  • Left ventricular ejection fraction (LVEF): To classify HF as HFrEF or HFpEF.
  • Ventricular size and function.
  • Valvular function and abnormalities.
  • Wall motion abnormalities.
  • Estimated pulmonary artery pressure.
  • Diastolic function assessment.

Additional Tests in Specific Cases:

• Stress Testing: To evaluate for ischemia as a cause of HF.
• Cardiac Catheterization and Coronary Angiography: To assess coronary artery disease directly, especially in patients with angina or suspected ischemic cardiomyopathy.
• Myocardial Biopsy: In selected cases of suspected myocarditis or infiltrative cardiomyopathies.
• Cardiac MRI: Provides detailed anatomical and functional assessment, helpful in cardiomyopathies and assessing viability.
• Radionuclide Ventriculography (MUGA Scan): Accurate assessment of LVEF, can be used if echocardiography is suboptimal. [42]

Medical Management and CHF Care Plan

The goals of medical management in a CHF care plan are to alleviate symptoms, improve functional status and quality of life, reduce hospitalizations, and prolong survival. Pharmacological and device therapies are integral components of CHF management.

Pharmacological Therapies:

• Diuretics: Loop diuretics (furosemide, bumetanide, torsemide) are used to manage fluid overload and alleviate symptoms of congestion. Thiazide diuretics may be added for synergistic effect or to manage hypertension in HFpEF. Diuretics are primarily for symptom relief and do not improve survival directly, but are crucial for quality of life.[3]
• Beta-Blockers: (Bisoprolol, carvedilol, metoprolol succinate) Reduce mortality and morbidity in HFrEF. Initiate at low doses and titrate up gradually. Not routinely used in acute decompensation.
• Angiotensin-Converting Enzyme Inhibitors (ACEIs) or Angiotensin Receptor Blockers (ARBs): (Enalapril, lisinopril, ramipril; Valsartan, losartan, candesartan) Reduce mortality and morbidity in HFrEF. ACEIs are generally preferred, but ARBs are used in ACEI-intolerant patients.
• Angiotensin Receptor-Neprilysin Inhibitor (ARNI): (Sacubitril/valsartan) Superior to ACEIs in reducing mortality and hospitalization in HFrEF (NYHA Class II-III). Recommended as first-line therapy in place of ACEI/ARB in eligible patients. [32, 33]
• Mineralocorticoid Receptor Antagonists (MRAs): (Spironolactone, eplerenone) Reduce mortality and morbidity in HFrEF (NYHA Class II-IV). Use with caution in patients with renal insufficiency or hyperkalemia.
• Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: (Dapagliflozin, empagliflozin) Demonstrated to reduce hospitalization for heart failure and cardiovascular death in both HFrEF and HFpEF, regardless of diabetes status. Becoming a cornerstone of CHF therapy.
• Hydralazine and Isosorbide Dinitrate: Combination therapy shown to improve survival in African Americans with HFrEF and persistent symptoms despite optimal therapy. [3]
• Digoxin: May improve symptoms and reduce hospitalizations in HFrEF, but does not improve survival. Used primarily for symptom control, particularly in patients with atrial fibrillation and rapid ventricular response.
• Vericiguat: A soluble guanylate cyclase stimulator, shown to reduce the risk of heart failure hospitalization and cardiovascular death in patients with HFrEF following a worsening heart failure event. [46, 47]

Device Therapies:

• Implantable Cardioverter-Defibrillator (ICD): For primary and secondary prevention of sudden cardiac death in patients with HFrEF and increased risk of ventricular arrhythmias.
• Cardiac Resynchronization Therapy (CRT): Biventricular pacing improves symptoms and survival in selected patients with HFrEF, left bundle branch block, and prolonged QRS duration. Often combined with ICD (CRT-D). [3]
• Ventricular Assist Devices (VADs): Mechanical circulatory support for advanced heart failure, used as a bridge to transplant or as destination therapy in patients not eligible for transplant.
• Cardiac Transplantation: Considered for patients with refractory end-stage heart failure despite optimal medical and device therapy.

Nursing Management and CHF Care Plan Implementation

Nursing care is integral to the CHF care plan diagnosis and management. Key nursing interventions focus on symptom management, patient education, and promoting adherence to therapy. [4]

Key Nursing Interventions:

• Relieving Fluid Overload Symptoms:
  • Administer diuretics as prescribed and monitor response (weight, urine output, edema, lung sounds).
  • Fluid restriction as ordered.
  • Sodium restriction education.
  • Positioning to promote venous return and reduce dyspnea (high Fowler’s position).
• Relieving Symptoms of Fatigue and Anxiety:
  • Promote rest and energy conservation.
  • Monitor activity tolerance and adjust activity levels accordingly.
  • Provide emotional support and address anxiety.
  • Educate on stress management techniques.
• Promoting Physical Activity:
  • Encourage regular, moderate exercise within tolerance (cardiac rehabilitation programs are beneficial).
  • Provide guidance on safe exercise and activity progression.
• Increasing Medication Compliance:
  • Thorough medication education (purpose, dosage, side effects).
  • Simplify medication regimens if possible.
  • Address barriers to adherence.
  • Utilize medication reminders or aids.
• Decreasing Adverse Effects of Treatment:
  • Monitor for and manage side effects of medications (e.g., electrolyte imbalances with diuretics, hypotension with vasodilators).
  • Educate patients on potential side effects and self-management strategies.
• Patient Education on Dietary Restrictions:
  • Low-sodium diet (typically 2-3 grams per day).
  • Fluid restriction (typically 2 liters per day, may be more restrictive in severe cases).
  • Educate on reading food labels and making healthy food choices.
• Patient Education on Self-Monitoring of Symptoms:
  • Daily weight monitoring and reporting significant changes.
  • Monitoring for edema, dyspnea, fatigue, and other symptoms.
  • Recognizing signs of worsening HF and when to seek medical attention.
• Patient Education on Daily Weight Monitoring:
  • Instruct on proper weighing technique (same time each day, same scale, after voiding, before breakfast).
  • Explain the importance of weight trends in managing fluid balance.

When to Seek Prompt Medical Attention

Patient education must emphasize when to seek immediate medical help. Prompt assessment is crucial in the following situations:

• Worsening Symptoms of Fluid Overload: Increased edema, rapid weight gain, worsening dyspnea, orthopnea, PND.
• Worsening Hypoxia: Increased shortness of breath, especially at rest, new onset or worsening cough, cyanosis.
• Uncontrolled Tachycardia: Persistent rapid heart rate, palpitations.
• Change in Cardiac Rhythm: Irregular heartbeat, new onset atrial fibrillation.
• Change in Mental Status: Confusion, dizziness, lightheadedness, syncope.
• Decreased Urinary Output: Despite usual diuretic therapy, indicating worsening renal perfusion and fluid retention.

Continuous Monitoring in CHF Care Plan

Ongoing monitoring is essential for patients with CHF to assess disease progression, treatment effectiveness, and identify early signs of decompensation.

Monitoring Parameters:

• Frequent Vital Signs Monitoring: Heart rate, blood pressure, respiratory rate, oxygen saturation.
• Telemetry Monitoring: Continuous heart rate and rhythm monitoring, especially during hospitalization or acute exacerbations.
• Symptom Assessment: Regular assessment of dyspnea, fatigue, edema, and other CHF symptoms.
• Daily Weight Monitoring: At home and in the hospital.
• Electrolyte Monitoring: Especially potassium, sodium, magnesium, and renal function (BUN, creatinine), particularly with diuretic and MRA use.
• BNP/NT-proBNP Monitoring: May be used to assess response to therapy and prognosis.

Interprofessional Coordination of Care

Optimal CHF care plan diagnosis and management necessitate a collaborative, interprofessional team approach. Team members typically include: [5]

• Primary Care Physician
• Cardiologist
• Emergency Department Physician
• Radiologist
• Cardiac Nurses (RNs, APRNs)
• Internist
• Cardiac Surgeons
• Pharmacist
• Dietitian
• Social Worker/Case Manager
• Rehabilitation Specialists (Physical and Occupational Therapists)

Effective communication and coordination among team members are crucial for delivering comprehensive and patient-centered care. The clinical nurse plays a vital role in patient education, care coordination, and ensuring adherence to the CHF care plan.

Health Education and Promotion in CHF

Patient education is a cornerstone of CHF management, aiming to improve clinical outcomes, reduce hospital readmissions, and enhance quality of life. [6]

Key Areas for Health Teaching:

• Self-Monitoring of Symptoms at Home: Emphasize daily weight, symptom awareness, and when to seek help.
• Medication Compliance: Importance of taking medications as prescribed, understanding medication names, dosages, timing, and side effects.
• Dietary Sodium Restriction: Educate on low-sodium diet principles, reading food labels, and meal planning.
• Fluid Restriction: Explain fluid restriction guidelines and strategies for managing thirst.
• Activity and Exercise Recommendations: Encourage regular physical activity within limitations, cardiac rehabilitation.
• Smoking Cessation: Strongly advise smoking cessation and provide resources.
• Alcohol Moderation or Abstinence: Counsel on limiting or avoiding alcohol consumption.
• Management of Comorbidities: Importance of managing diabetes, hypertension, hyperlipidemia, and sleep apnea.
• Vaccinations: Influenza and pneumococcal vaccination recommended.
• Sleep Apnea Management: Encourage CPAP therapy for patients with sleep apnea and CHF.

Discharge Planning for CHF Patients

Effective discharge planning is crucial to ensure a smooth transition from hospital to home and prevent readmissions. Discharge planning should begin upon admission and include:

• Medication Reconciliation and Education: Review all medications, ensure patient understanding of medication regimen, provide written discharge medication list.
• Dietary and Fluid Restriction Reinforcement: Review dietary and fluid restrictions.
• Activity and Exercise Guidelines: Provide personalized activity recommendations.
• Smoking Cessation Resources: Offer continued support for smoking cessation.
• Recognition of Worsening HF Symptoms and Action Plan: Reinforce warning signs and provide a clear plan for seeking medical attention.
• Follow-up Appointments: Schedule timely follow-up appointments with primary care physician and cardiologist.
• Referral to Home Health Care or Cardiac Rehabilitation: As appropriate.
• Community Resources: Connect patients with community resources and support groups.
• Nurse-Driven Education at Discharge: Has been shown to improve therapy compliance and patient outcomes. [6]

Conclusion

Accurate CHF care plan diagnosis and comprehensive management are essential for improving outcomes in patients with heart failure. A multidisciplinary approach, incorporating thorough assessment, diagnostic testing, pharmacological and device therapies, nursing care, and patient education, is critical. By focusing on early diagnosis, addressing modifiable risk factors, and implementing evidence-based CHF care plans, healthcare professionals can significantly impact the lives of individuals living with this chronic condition, enhancing their quality of life and longevity.

References

1.Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW., ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 03;145(18):e895-e1032. [PubMed: 35363499]

2.Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016 Jun;13(6):368-78. [PMC free article: PMC4868779] [PubMed: 26935038]

3.CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987 Jun 04;316(23):1429-35. [PubMed: 2883575]

4.Lind L, Ingelsson M, Sundstrom J, Ärnlöv J. Impact of risk factors for major cardiovascular diseases: a comparison of life-time observational and Mendelian randomisation findings. Open Heart. 2021 Sep;8(2) [PMC free article: PMC8438838] [PubMed: 34518286]

5.Noubiap JJ, Agbor VN, Bigna JJ, Kaze AD, Nyaga UF, Mayosi BM. Prevalence and progression of rheumatic heart disease: a global systematic review and meta-analysis of population-based echocardiographic studies. Sci Rep. 2019 Nov 19;9(1):17022. [PMC free article: PMC6863880] [PubMed: 31745178]

6.Kim KH, Pereira NL. Genetics of Cardiomyopathy: Clinical and Mechanistic Implications for Heart Failure. Korean Circ J. 2021 Oct;51(10):797-836. [PMC free article: PMC8484993] [PubMed: 34327881]

7.Rezkalla SH, Kloner RA. Viral myocarditis: 1917-2020: From the Influenza A to the COVID-19 pandemics. Trends Cardiovasc Med. 2021 Apr;31(3):163-169. [PMC free article: PMC7965406] [PubMed: 33383171]

8.Muchtar E, Blauwet LA, Gertz MA. Restrictive Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circ Res. 2017 Sep 15;121(7):819-837. [PubMed: 28912185]

9.Shams P, Ahmed I. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 30, 2023. Cardiac Amyloidosis. [PubMed: 35593829]

10.Brown KN, Pendela VS, Ahmed I, Diaz RR. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 30, 2023. Restrictive Cardiomyopathy. [PubMed: 30725919]

11.Matta AG, Carrié D. Epidemiology, Pathophysiology, Diagnosis, and Principles of Management of Takotsubo Cardiomyopathy: A Review. Med Sci Monit. 2023 Mar 06;29:e939020. [PMC free article: PMC9999670] [PubMed: 36872594]

12.Bairashevskaia AV, Belogubova SY, Kondratiuk MR, Rudnova DS, Sologova SS, Tereshkina OI, Avakyan EI. Update of Takotsubo cardiomyopathy: Present experience and outlook for the future. Int J Cardiol Heart Vasc. 2022 Apr;39:100990. [PMC free article: PMC8913320] [PubMed: 35281752]

13.Ahmad SA, Brito D, Khalid N, Ibrahim MA. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 22, 2023. Takotsubo Cardiomyopathy. [PubMed: 28613549]

14.DeFilippis EM, Beale A, Martyn T, Agarwal A, Elkayam U, Lam CSP, Hsich E. Heart Failure Subtypes and Cardiomyopathies in Women. Circ Res. 2022 Feb 18;130(4):436-454. [PMC free article: PMC10361647] [PubMed: 35175847]

15.Wong CM, Hawkins NM, Jhund PS, MacDonald MR, Solomon SD, Granger CB, Yusuf S, Pfeffer MA, Swedberg K, Petrie MC, McMurray JJ. Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity). J Am Coll Cardiol. 2013 Nov 12;62(20):1845-54. [PubMed: 23850914]

16.Sciomer S, Moscucci F, Salvioni E, Marchese G, Bussotti M, Corrà U, Piepoli MF. Role of gender, age and BMI in prognosis of heart failure. Eur J Prev Cardiol. 2020 Dec;27(2_suppl):46-51. [PMC free article: PMC7691623] [PubMed: 33238736]

17.Volpe M, Gallo G. Obesity and cardiovascular disease: An executive document on pathophysiological and clinical links promoted by the Italian Society of Cardiovascular Prevention (SIPREC). Front Cardiovasc Med. 2023;10:1136340. [PMC free article: PMC10040794] [PubMed: 36993998]

18.Kim DY, Kim SH, Ryu KH. Tachycardia induced Cardiomyopathy. Korean Circ J. 2019 Sep;49(9):808-817. [PMC free article: PMC6713829] [PubMed: 31456374]

19.Anakwue RC, Onwubere BJ, Anisiuba BC, Ikeh VO, Mbah A, Ike SO. Congestive heart failure in subjects with thyrotoxicosis in a black community. Vasc Health Risk Manag. 2010 Aug 09;6:473-7. [PMC free article: PMC2922308] [PubMed: 20730063]

20.Schoenenberger AW, Schoenenberger-Berzins R, der Maur CA, Suter PM, Vergopoulos A, Erne P. Thiamine supplementation in symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled, cross-over pilot study. Clin Res Cardiol. 2012 Mar;101(3):159-64. [PubMed: 22057652]

21.DiNicolantonio JJ, Liu J, O’Keefe JH. Thiamine and Cardiovascular Disease: A Literature Review. Prog Cardiovasc Dis. 2018 May-Jun;61(1):27-32. [PubMed: 29360523]

22.Reddy YNV, Melenovsky V, Redfield MM, Nishimura RA, Borlaug BA. High-Output Heart Failure: A 15-Year Experience. J Am Coll Cardiol. 2016 Aug 02;68(5):473-482. [PubMed: 27470455]

23.Chayanupatkul M, Liangpunsakul S. Cirrhotic cardiomyopathy: review of pathophysiology and treatment. Hepatol Int. 2014 Jul;8(3):308-15. [PMC free article: PMC4160726] [PubMed: 25221635]

24.Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Shay CM, Spartano NL, Stokes A, Tirschwell DL, VanWagner LB, Tsao CW., American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation. 2020 Mar 03;141(9):e139-e596. [PubMed: 31992061]

25.Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993 Oct;22(4 Suppl A):6A-13A. [PubMed: 8376698]

26.Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P., American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017 Mar 07;135(10):e146-e603. [PMC free article: PMC5408160] [PubMed: 28122885]

27.Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, Brauer M, Kutty VR, Gupta R, Wielgosz A, AlHabib KF, Dans A, Lopez-Jaramillo P, Avezum A, Lanas F, Oguz A, Kruger IM, Diaz R, Yusoff K, Mony P, Chifamba J, Yeates K, Kelishadi R, Yusufali A, Khatib R, Rahman O, Zatonska K, Iqbal R, Wei L, Bo H, Rosengren A, Kaur M, Mohan V, Lear SA, Teo KK, Leong D, O’Donnell M, McKee M, Dagenais G. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet. 2020 Mar 07;395(10226):795-808. [PMC free article: PMC8006904] [PubMed: 31492503]

28.Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodelling. Lancet. 2006 Jan 28;367(9507):356-67. [PubMed: 16443044]

29.Kemp CD, Conte JV. The pathophysiology of heart failure. Cardiovasc Pathol. 2012 Sep-Oct;21(5):365-71. [PubMed: 22227365]

30.Ait Mou Y, Bollensdorff C, Cazorla O, Magdi Y, de Tombe PP. Exploring cardiac biophysical properties. Glob Cardiol Sci Pract. 2015;2015:10. [PMC free article: PMC4448074] [PubMed: 26779498]

31.Abassi Z, Khoury EE, Karram T, Aronson D. Edema formation in congestive heart failure and the underlying mechanisms. Front Cardiovasc Med. 2022;9:933215. [PMC free article: PMC9553007] [PubMed: 36237903]

32.Prausmüller S, Arfsten H, Spinka G, Freitag C, Bartko PE, Goliasch G, Strunk G, Pavo N, Hülsmann M. Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF. J Am Heart Assoc. 2020 Jun 02;9(11):e015071. [PMC free article: PMC7428996] [PubMed: 32427034]

33.Docherty KF, Vaduganathan M, Solomon SD, McMurray JJV. Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF. JACC Heart Fail. 2020 Oct;8(10):800-810. [PMC free article: PMC8837825] [PubMed: 33004114]

34.Obokata M, Reddy YNV, Borlaug BA. Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: Understanding Mechanisms by Using Noninvasive Methods. JACC Cardiovasc Imaging. 2020 Jan;13(1 Pt 2):245-257. [PMC free article: PMC6899218] [PubMed: 31202759]

35.Kao DP, Lewsey JD, Anand IS, Massie BM, Zile MR, Carson PE, McKelvie RS, Komajda M, McMurray JJ, Lindenfeld J. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. Eur J Heart Fail. 2015 Sep;17(9):925-35. [PMC free article: PMC4654630] [PubMed: 26250359]

36.Harjola VP, Mullens W, Banaszewski M, Bauersachs J, Brunner-La Rocca HP, Chioncel O, Collins SP, Doehner W, Filippatos GS, Flammer AJ, Fuhrmann V, Lainscak M, Lassus J, Legrand M, Masip J, Mueller C, Papp Z, Parissis J, Platz E, Rudiger A, Ruschitzka F, Schäfer A, Seferovic PM, Skouri H, Yilmaz MB, Mebazaa A. Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2017 Jul;19(7):821-836. [PMC free article: PMC5734941] [PubMed: 28560717]

37.King M, Kingery J, Casey B. Diagnosis and evaluation of heart failure. Am Fam Physician. 2012 Jun 15;85(12):1161-8. [PubMed: 22962896]

38.Ali AS, Rybicki BA, Alam M, Wulbrecht N, Richer-Cornish K, Khaja F, Sabbah HN, Goldstein S. Clinical predictors of heart failure in patients with first acute myocardial infarction. Am Heart J. 1999 Dec;138(6 Pt 1):1133-9. [PubMed: 10577445]

39.Klein L, O’Connor CM, Leimberger JD, Gattis-Stough W, Piña IL, Felker GM, Adams KF, Califf RM, Gheorghiade M., OPTIME-CHF Investigators. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation. 2005 May 17;111(19):2454-60. [PubMed: 15867182]

40.Kelder JC, Cramer MJ, van Wijngaarden J, van Tooren R, Mosterd A, Moons KG, Lammers JW, Cowie MR, Grobbee DE, Hoes AW. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation. 2011 Dec 20;124(25):2865-73. [PubMed: 22104551]

41.Rørth R, Jhund PS, Yilmaz MB, Kristensen SL, Welsh P, Desai AS, Køber L, Prescott MF, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Packer M, McMurray JJV. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. Circ Heart Fail. 2020 Feb;13(2):e006541. [PubMed: 32065760]

42.Hacker M, Hoyer X, Kupzyk S, La Fougere C, Kois J, Stempfle HU, Tiling R, Hahn K, Störk S. Clinical validation of the gated blood pool SPECT QBS processing software in congestive heart failure patients: correlation with MUGA, first-pass RNV and 2D-echocardiography. Int J Cardiovasc Imaging. 2006 Jun-Aug;22(3-4):407-16. [PubMed: 16328851]

43.Jain S, Londono FJ, Segers P, Gillebert TC, De Buyzere M, Chirinos JA. MRI Assessment of Diastolic and Systolic Intraventricular Pressure Gradients in Heart Failure. Curr Heart Fail Rep. 2016 Feb;13(1):37-46. [PubMed: 26780916]

44.Cahill TJ, Ashrafian H, Watkins H. Genetic cardiomyopathies causing heart failure. Circ Res. 2013 Aug 30;113(6):660-75. [PubMed: 23989711]

45.Peterson PN, Rumsfeld JS, Liang L, Albert NM, Hernandez AF, Peterson ED, Fonarow GC, Masoudi FA., American Heart Association Get With the Guidelines-Heart Failure Program. A validated risk score for in-hospital mortality in patients with heart failure from the American Heart Association get with the guidelines program. Circ Cardiovasc Qual Outcomes. 2010 Jan;3(1):25-32. [PubMed: 20123668]

46.Lam CSP, Mulder H, Lopatin Y, Vazquez-Tanus JB, Siu D, Ezekowitz J, Pieske B, O’Connor CM, Roessig L, Patel MJ, Anstrom KJ, Hernandez AF, Armstrong PW., VICTORIA Study Group. Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial. J Am Heart Assoc. 2021 Nov 16;10(22):e021094. [PMC free article: PMC8751950] [PubMed: 34743540]

47.Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O’Connor CM., VICTORIA Study Group. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020 May 14;382(20):1883-1893. [PubMed: 32222134]

48.Lucas C, Johnson W, Hamilton MA, Fonarow GC, Woo MA, Flavell CM, Creaser JA, Stevenson LW. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J. 2000 Dec;140(6):840-7. [PubMed: 11099986]

49.Rider I, Sorensen M, Brady WJ, Gottlieb M, Benson S, Koyfman A, Long B. Disposition of acute decompensated heart failure from the emergency department: An evidence-based review. Am J Emerg Med. 2021 Dec;50:459-465. [PubMed: 34500232]